Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Nensi Shrestha"'
Autor:
Nensi Shrestha, Zabeen Lateef, Orleans Martey, Abigail R. Bland, Mhairi Nimick, Rhonda Rosengren, John C. Ashton
Publikováno v:
F1000Research, Vol 8 (2019)
Lung cancer drug development requires screening in animal models. We aimed to develop orthotopic models of human non-small lung cancer using A549 and H3122 cells delivered by tail vein injection. This procedure has been used previously for a mouse lu
Externí odkaz:
https://doaj.org/article/ea9d4aefef0546e585750238b98f57ec
Publikováno v:
Current Cancer Drug Targets. 22:97-107
Abstract: Mathematical modelling of tumour mutation dynamics has suggested that cancer drug targets that have different resistance mechanisms should be good candidates for combination treatment. This is because the development of mutations that cause
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27a04216cbc6ddc51a206a83b986efcc
https://doi.org/10.2174/1568009622666220107152014
https://doi.org/10.2174/1568009622666220107152014
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 374:134-140
Anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer most commonly arises through EML4 (Echinoderm Microtuble Like 4)-ALK chromosomal fusion. We have previously demonstrated that combination of the ALK inhibitor crizotinib with the ME
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd5add7be512b8769e7a10bdfef2c2cc
https://doi.org/10.1124/jpet.120.266049
https://doi.org/10.1124/jpet.120.266049
Publikováno v:
Pharmacology. 105:715-718
Crizotinib is a tyrosine kinase inhibitor used to treat anaplastic lymphoma kinase-positive lung cancer. There is in vitro evidence that crizotinib may auto-inhibit cytochrome P450 3A (CYP3A) activity, with important implications for crizotinib pharm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c3d2d64270210ce7f52dcecee37c553a
https://doi.org/10.1159/000506996
https://doi.org/10.1159/000506996
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Scientific Reports
Scientific Reports, Vol 9, Iss 1, Pp 1-12 (2019)
Scientific Reports, Vol 9, Iss 1, Pp 1-12 (2019)
Anaplastic lymphoma kinase (ALK) rearrangement, a key oncogenic driver in a small subset of non-small cell lung cancers, confers sensitivity to ALK tyrosine kinase inhibitors (TKIs). Crizotinib, a first generation ALK-TKI, has superiority to standard
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0799a40f9c590e27fadffd1e73d8ef02
https://pubmed.ncbi.nlm.nih.gov/31827192
https://pubmed.ncbi.nlm.nih.gov/31827192
Autor:
Rhonda J. Rosengren, Mhairi Nimick, Nensi Shrestha, Orleans N. K. Martey, John C. Ashton, Abigail R. Bland, Zabeen Lateef
Publikováno v:
F1000Research
Lung cancer drug development requires screening in animal models. We aimed to develop orthotopic models of human non-small lung cancer using A549 and H3122 cells delivered by tail vein injection. This procedure has been used previously for a mouse lu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ebee2cc54f47acdaaa6af7215a3b2e2
https://pubmed.ncbi.nlm.nih.gov/31448098
https://pubmed.ncbi.nlm.nih.gov/31448098
Autor:
Young-Chang Cho, Nensi Shrestha, Hridaya Shrestha, Taeyong Ryu, Woo Keun Song, Young-Woo Seo, Yongfeng He, Kwonseop Kim, Tingting Yuan, Hangun Kim
Publikováno v:
Scientific Reports
SCIENTIFIC REPORTS(6)
SCIENTIFIC REPORTS(6)
Expression of δ-catenin reportedly increases during late stage prostate cancer. Furthermore, it has been demonstrated that expression of EGFR is enhanced in hormone refractory prostate cancer. In this study, we investigated the possible correlation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cb3caca16ebe2edf6c48aa186af7169
http://europepmc.org/articles/PMC4756308
http://europepmc.org/articles/PMC4756308
Autor:
Yongfeng He, Young-Chang Cho, Tingting Yuan, Taeyong Ryu, Moon-Chang Baek, Nensi Shrestha, Sayeon Cho, Kwonseop Kim, Hridaya Shrestha, So-Yeon Park, Shishli Simkhada, Pyong-Gon Moon, Hangun Kim, Chan-Hyeong Lee
Publikováno v:
Biochimica et biophysica acta. 1863(9)
Ubiquitination, a post-translational modification, involves the covalent attachment of ubiquitin to the target protein. The ubiquitin-proteasome pathway and the endosome-lysosome pathway control the degradation of the majority of eukaryotic proteins.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6dae99b3e3552e2a0eec2f4d71b26a5
https://pubmed.ncbi.nlm.nih.gov/27316454
https://pubmed.ncbi.nlm.nih.gov/27316454